1254160-17-2Relevant articles and documents
METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION
-
, (2016/06/28)
The present invention is directed to selective adenosine A1 agonist compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat, reduce or prevent age-related macular degeneration.
COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE
-
, (2011/08/02)
The present invention is directed to a combination or a kit comprising a prostaglandin analog and an adenosine receptor A1 agonist and to a method of reducing intraocular pressure (IOP) in a subject using such combination or kit. The invention is particularly directed to a combination of latanoprost marketed under the brand Xalatan? and Compound A.